Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 20;7(12):659.
doi: 10.1038/s41408-017-0023-x.

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

E Mejstríková  1 , O Hrusak  1 , M J Borowitz  2 , J A Whitlock  3 , B Brethon  4 , T M Trippett  5 , G Zugmaier  6 , L Gore  7 , A von Stackelberg  8 , F Locatelli  9   10
Affiliations

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

E Mejstríková et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests

E.M., O.H., and M.J.B. performed MRD assessments as a service to Amgen. M.J.B. reports research grants from Becton Dickinson Biosciences and participated on a speakers bureau for Beckman Coulter. J.A.W. reports research grants/funding for trials from Novartis and Amgen and consulting fees from Jazz Pharmaceuticals, Shire, Amgen, and Gilead. G.Z. is an employee of and owns stock in Amgen. L.G. received consulting fees from Amgen, Novartis, and Celgene; is on the board of directors for Round River Ranch/Serious Fun Network; and owns stock in Amgen, Celgene, Clovis Oncology, and Sanofi PARIS. A.V.S. reports consulting fees from Amgen. The remaining authors (B.B., T.M.T., and F.L.) declare that they have no competing financial interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Flow cytometric profiles of blasts from four patients with CD19-negative relapse after blinatumomab treatment and one control patient during treatment. a Patient #1, b Patient #2, c Patient #3, d Patient #4, and e control patient
See this image and copyright information in PMC

References

    1. Ruella M, Maus MV. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput. Struct. Biotechnol. J. 2016;14:357–362. doi: 10.1016/j.csbj.2016.09.003. - DOI - PMC - PubMed
    1. Rayes A, McMasters RL, O’Brien MM. Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr. Blood Cancer. 2016;63:1113–1115. doi: 10.1002/pbc.25953. - DOI - PubMed
    1. Sotillo E, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295. doi: 10.1158/2159-8290.CD-15-1020. - DOI - PMC - PubMed
    1. Gardner R, et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood. 2016;127:2406–2410. doi: 10.1182/blood-2015-08-665547. - DOI - PMC - PubMed
    1. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr. J. Hematol. Infect. Dis. 2014;6:e2014073. doi: 10.4084/mjhid.2014.073. - DOI - PMC - PubMed

Publication types

MeSH terms